Status:
COMPLETED
Acetazolamide for Respiratory Failure in Combination With Metabolic Alkalosis
Lead Sponsor:
University of Oslo School of Pharmacy
Conditions:
Respiratory Insufficiency
Alkalosis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Respiratory failure is a common consequence of chronic obstructive pulmonary disease (COPD). A concurrent metabolic alkalosis may worsen the respiratory failure, as a higher pH in blood (and thus in c...
Eligibility Criteria
Inclusion
- Arterial pO2 8 kPa or lower, and arterial pCO2 7 kPa or higher.
- Base Excess 8 mmmol/l or higher.
- Written informed consent
Exclusion
- Acetazolamide treatment regarded as obviously indicated or obviously contraindicated
- Already using acetazolamide
- Moribund patient
- Unable to give fully informed consent
- Allergy towards the tablet content or unable to swallow the tablets
- Pregnant or breast-feeding
Key Trial Info
Start Date :
January 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00222534
Start Date
January 1 2002
End Date
December 1 2009
Last Update
January 20 2014
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Respiratory Medicine, Haukeland University Hospital
Bergen, Norway
2
Department of Internal Medicine, Sorlandet Sykehus Kristiansand
Kristiansand, Norway
3
Department of Internal Medicine, Aker University Hospital
Oslo, Norway, 0514
4
Ullevaal University Hospital, Dept. of Respiratory Medicine
Oslo, Norway, NO-0407